🇺🇸 FDA
Patent

US 11638753

Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

granted A61KA61K2039/55505A61K2039/55522

Quick answer

US patent 11638753 (Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy) held by PDS Biotechnology Corporation expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PDS Biotechnology Corporation
Grant date
Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/55505, A61K2039/55522, A61K2039/55555, A61K2039/55572